- Home
- PMT vs GYRE Comparison
PMT vs GYRE Comparison
Compare PMT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMT
- GYRE
- Stock Information
- Founded
- PMT 2009
- GYRE 2002
- Country
- PMT United States
- GYRE United States
- Employees
- PMT N/A
- GYRE N/A
- Industry
- PMT Real Estate Investment Trusts
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- PMT Real Estate
- GYRE Health Care
- Exchange
- PMT Nasdaq
- GYRE Nasdaq
- Market Cap
- PMT 1.1B
- GYRE 1.1B
- IPO Year
- PMT 2009
- GYRE N/A
- Fundamental
- Price
- PMT $12.55
- GYRE $10.60
- Analyst Decision
- PMT Buy
- GYRE
- Analyst Count
- PMT 6
- GYRE 0
- Target Price
- PMT $15.25
- GYRE N/A
- AVG Volume (30 Days)
- PMT 747.8K
- GYRE 111.4K
- Earning Date
- PMT 01-30-2025
- GYRE 11-13-2024
- Dividend Yield
- PMT 12.75%
- GYRE N/A
- EPS Growth
- PMT 16.86
- GYRE N/A
- EPS
- PMT 1.41
- GYRE N/A
- Revenue
- PMT $807,048,000.00
- GYRE $105,033,000.00
- Revenue This Year
- PMT N/A
- GYRE $25.32
- Revenue Next Year
- PMT $21.33
- GYRE $12.95
- P/E Ratio
- PMT $8.90
- GYRE N/A
- Revenue Growth
- PMT 57.27
- GYRE N/A
- 52 Week Low
- PMT $11.77
- GYRE $8.26
- 52 Week High
- PMT $15.22
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- PMT 44.37
- GYRE 46.02
- Support Level
- PMT $11.77
- GYRE $10.58
- Resistance Level
- PMT $12.80
- GYRE $11.36
- Average True Range (ATR)
- PMT 0.20
- GYRE 0.70
- MACD
- PMT 0.05
- GYRE 0.06
- Stochastic Oscillator
- PMT 75.73
- GYRE 32.63
About PMT PennyMac Mortgage Investment Trust of Beneficial Interest
PennyMac Mortgage Investment Trust is a specialty finance company that invests primarily in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through four segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies, and corporate activities. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.